Buscar
Neumora Therapeutics Inc
NMRAAñadir a la lista de seguimiento
1.610USD
-0.040-2.42%
Cierre 07-31 16:00（ET）Cotizaciones retrasadas 15 min
298.31MCap. mercado
PérdidaP/E TTM
Más Datos de Neumora Therapeutics Inc Compañía
Neumora Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company's therapeutic pipeline consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its advanced product candidate, navacaprant (NMRA-140), is a novel once-daily oral kappa opioid receptor (KOR) antagonist that is being developed for the treatment of depressive disorder (MDD). Navacaprant is being investigated in the KOASTAL pivotal Phase 3 program, evaluating navacaprant monotherapy in patients with moderate to severe MDD. The Company's next advanced product candidate is NMRA-511, which is a highly selective, novel antagonist of the vasopressin 1a receptor (V1aR) being developed for the treatment of agitation associated with dementia due to Alzheimer's disease (AD).
Información de Neumora Therapeutics Inc
Símbolo de cotizaciónNMRA
Nombre de la empresaNeumora Therapeutics Inc
Fecha de salida a bolsaSep 15, 2023
Director ejecutivoBerns (Paul L)
Número de empleados110
Tipo de seguridadOrdinary Share
Fin del año fiscalSep 15
Dirección260 Arsenal Place, Suite 1
CiudadWATERTOWN
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal02472
Teléfono18577600900
Sitio Webhttps://neumoratx.com/
Símbolo de cotizaciónNMRA
Fecha de salida a bolsaSep 15, 2023
Director ejecutivoBerns (Paul L)
Ejecutivos de Neumora Therapeutics Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Paul L. Berns
Mr. Paul L. Berns
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
7.71M
+0.56%
Ms. Kristina M. Burow
Ms. Kristina M. Burow
Independent Director
Independent Director
47.72K
--
Dr. Daljit Singh (Bill) Aurora, Pharm.D.
Dr. Daljit Singh (Bill) Aurora, Pharm.D.
Chief Operating and Development Officer
Chief Operating and Development Officer
34.02K
-265.51%
Mr. Michael Lee Milligan
Mr. Michael Lee Milligan
Chief Financial Officer, Principal Accounting Officer
Chief Financial Officer, Principal Accounting Officer
21.03K
-6.83%
Dr. Maykin Ho, Ph.D.
Dr. Maykin Ho, Ph.D.
Independent Director
Independent Director
20.10K
--
Dr. Joshua Pinto, Ph.D.
Dr. Joshua Pinto, Ph.D.
President
President
--
--
Mr. Alaa A. Halawa
Mr. Alaa A. Halawa
Independent Director
Independent Director
--
--
Mr. Matthew K. (Matt) Fust
Mr. Matthew K. (Matt) Fust
Independent Director
Independent Director
--
--
Mr. David Piacquad
Mr. David Piacquad
Independent Director
Independent Director
--
--
Ms. Helen Rubinstein
Ms. Helen Rubinstein
IR Contact Officer
IR Contact Officer
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Paul L. Berns
Mr. Paul L. Berns
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
7.71M
+0.56%
Ms. Kristina M. Burow
Ms. Kristina M. Burow
Independent Director
Independent Director
47.72K
--
Dr. Daljit Singh (Bill) Aurora, Pharm.D.
Dr. Daljit Singh (Bill) Aurora, Pharm.D.
Chief Operating and Development Officer
Chief Operating and Development Officer
34.02K
-265.51%
Mr. Michael Lee Milligan
Mr. Michael Lee Milligan
Chief Financial Officer, Principal Accounting Officer
Chief Financial Officer, Principal Accounting Officer
21.03K
-6.83%
Dr. Maykin Ho, Ph.D.
Dr. Maykin Ho, Ph.D.
Independent Director
Independent Director
20.10K
--
Dr. Joshua Pinto, Ph.D.
Dr. Joshua Pinto, Ph.D.
President
President
--
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Neumora Therapeutics Inc?
Los cinco principales accionistas de Neumora Therapeutics Inc son: Mr. Paul L. Berns
¿Cuántas instituciones poseen acciones de Neumora Therapeutics Inc (NMRA)?
A fecha de 2026Q1, 301 instituciones poseen acciones de Neumora Therapeutics Inc, con un valor de mercado combinado de aproximadamente 106.55M, lo que representa el 57.52% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -16535931.00.